2. Search Result
Search Result
Pathways Recommended: TGF-beta/Smad
Results for "

TGFβRI

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

3

Natural
Products

1

Recombinant Proteins

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13226
    Galunisertib
    Maximum Cited Publications
    68 Publications Verification

    LY2157299

    		 TGF-β Receptor Cancer
    Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
    Galunisertib
  • HY-N0439
    Asiaticoside
    15+ Cited Publications

    		 p38 MAPK TGF-beta/Smad Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.
    Asiaticoside
  • HY-13462
    LY-364947
    20+ Cited Publications

    HTS466284

    		 TGF-β Receptor Cancer
    LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM, and exhibits 7-fold selectivity over TGFβR-II .
    LY-364947
  • HY-13227
    SD-208
    5+ Cited Publications

    		 TGF-β Receptor Cancer
    SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, and > 100-fold selectivity over TGF-βRII.
    SD-208
  • HY-N0439R
    Asiaticoside (Standard)

    		p38 MAPK Reference Standards TGF-beta/Smad Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Asiaticoside (Standard) is the analytical standard of Asiaticoside. This product is intended for research and analytical applications. Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.
    Asiaticoside (Standard)
  • HY-137918
    TGF-βRI inhibitor 3

    		Src TGF-β Receptor Anaplastic lymphoma kinase (ALK) Others
    TGF-βRI inhibitor 3 (Compound 9ac) is a selective TGF-β inhibitor. TGF-βRI inhibitor 3 can effectively inhibit the TGF-β signaling pathway. TGF-βRI inhibitor 3 has IC50 values of 13 μM and 0.63 μM for c-Src kinase and ALK5 kinase, respectively .
    TGF-βRI inhibitor 3
  • HY-144043
    ALK5-IN-8

    		TGF-β Receptor Cancer
    ALK5-IN-8 is a potent inhibitor of TGFβRI (ALK5). ALK5-IN-8 Inhibits the phosphorylation of ALK5 on its downstream signaling proteins (Smad2 or Smad3) by blocking the binding of TGFβRI to ligands, thereby affecting or blocking TGF-β signaling. ALK5-IN-8 has the potential for the research of various ALK5-mediated related diseases (extracted from patent WO2021190425A1, compound 1) .
    ALK5-IN-8
  • HY-132290
    TGFβRI-IN-3

    		TGF-β Receptor Inflammation/Immunology Cancer
    TGFβRI-IN-3 inhibits TGFβR1 at an IC50 of 0.79 nM with 2000-fold selectivity against MAP4K4. TGFβRI-IN-3 represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology .
    TGFβRI-IN-3
  • HY-125851
    TP-008

    		TGF-β Receptor Inflammation/Immunology
    TP-008, a chemical probe, is a potent, selective and orally active (Activin-Like Kinase 5) ALK5 inhibitor with pIC50 and pEC50 values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose .
    TP-008
  • HY-171878
    BI-4659

    		TGF-β Receptor PDGFR TGF-beta/Smad Inflammation/Immunology Cancer
    BI-4659 is a TGFβRI and PDGFRα inhibitor with IC50 values of 19 nM and 99 nM, respectively. BI-4659 inhibits the kinase activities of TGFβRI and PDGFRα, blocks the downstream TGFβRI signaling pathway, and reduces the phosphorylation level of Smad2/3 without altering the expression of TGF-β1. BI-4659 is applicable to research related to pulmonary fibrosis, cancer, and renal ischemia-reperfusion injury .
    BI-4659
  • HY-W028145
    TGF-βRI inhibitor 2

    		TGF-β Receptor Cancer
    TGF-βRI inhibitor 2 (compound 13) is a TGF-βRI inhibitor. TGF-βRI inhibitor 2 can be used in cancer research .
    TGF-βRI inhibitor 2
  • HY-112864
    TGFβRI-IN-6

    		TGF-β Receptor Inflammation/Immunology Cancer
    TGFβRI-IN-6 (compound 22) is a potent TGFβRI inhibitor with an IC50 value of 0.55 nM. TGFβRI-IN-6 has the potential to enhance anti-tumor immunity .
    TGFβRI-IN-6
  • HY-178231
    ALK5-IN-85

    		TGF-β Receptor Inflammation/Immunology Cancer
    ALK5-IN-85 (Compound 19) is a TGFβRI (ALK5) inhibitor with an IC50 < 100 ?nM. ALK5-IN-85 can be used for respiratory diseases including idiopathic pulmonary fibrosis, asthma, COPD and lumg cancer, and dermal and ocular fibrotic conditions research .
    ALK5-IN-85
  • HY-13226A
    Galunisertib monohydrate

    		TGF-β Receptor Cancer
    Galunisertib monohydrate is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
    Galunisertib monohydrate
  • HY-13226R
    Galunisertib (Standard)

    LY2157299 (Standard)

    		 TGF-β Receptor Reference Standards Cancer
    Galunisertib (Standard) is the analytical standard of Galunisertib. This product is intended for research and analytical applications. Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
    Galunisertib (Standard)
  • HY-144437
    ALK5-IN-9

    		TGF-β Receptor Cancer
    ALK5-IN-9 (Compound 8h) is a potent and orally active inhibitor of TGFβRI (ALK5). ALK5-IN-9 inhibits ALK5 autophosphorylation and NIH3T3 cell activity with IC50 values of 25 nM and 74.6 nM, respectively. ALK5-IN-9 also shows favorable pharmacokinetic profile and ameliorated hERG inhibition. ALK5-IN-9 has the potential for the research of cancer disease .
    ALK5-IN-9
  • HY-114192
    TGFβRI-IN-1

    		TGF-β Receptor Cancer
    TGFβRI-IN-1 is an oral active and selective TGFβ receptor type I (TGFβRI) kinase inhibitor, with IC50 values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively .
    TGFβRI-IN-1
  • HY-172108
    TGFβRI-IN-7

    		TGF-β Receptor Cancer
    TGFβRI-IN-7 (compound 16W) is a potent inhibitor of TGFβRI. TGFβRI-IN-7 inhibits SMAD2/3 phosphorylation and H22 cell viability with IC50 values of 12 and 65 nM, respectively. TGFβRI-IN-7 shows anti-tumor efficacy in a xenograft model of H22 cells, with TGI of 79.6 % .
    TGFβRI-IN-7
  • HY-147786
    TGFβRI-IN-5

    		TGF-β Receptor Cancer
    TGFβRI-IN-5 (Compound 4b) is a potent inhibitor of TGFβRI with an IC50 of 0.08 μM. TGFβRI-IN-5 displays amazing anticancer activity 5–7 times that of reference agent against all the tested cell lines. TGFβRI-IN-5 enhances apoptosis and arrested G2/M phase of cell cycle .
    TGFβRI-IN-5
  • HY-146780
    TGFβRI-IN-4

    		TGF-β Receptor Cancer
    TGFβRI-IN-4 is a highly potent and orally active TGFβ receptor type I (TGFβRI) inhibitor, with IC50s of 44 nM and 42.5 nM for ALK5 and NIH3T3. TGFβRI-IN-4 can suppress tumor growth and tumor weight in tumor xenograft model .
    TGFβRI-IN-4
  • HY-13227R
    SD-208 (Standard)

    		TGF-β Receptor Cancer
    SD-208 (Standard) is the analytical standard of SD-208. This product is intended for research and analytical applications. SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, and > 100-fold selectivity over TGF-βRII.
    SD-208 (Standard)
  • HY-N17639
    Regiafuran C

    		TGF-beta/Smad TGF-β Receptor Others
    Regiafuran C is a compound with both TGF-βRI inhibitory and anti-fibrotic activities. Regiafuran C effectively inhibits renal fibrosis by binding to TGF-βRI and interfering with the TGF-β/Smad and Wnt/β-catenin signaling pathways. Regiafuran C also exhibits free radical scavenging activity, but shows no anti-inflammatory activity in PGE2 competitive enzyme immunoassays. The ability of Regiafuran C to specifically block the Smad3-TGF-βRII interaction and inhibit fibrotic processes allows its use in renal fibrosis research .
    Regiafuran C
  • HY-13227G
    SD-208

    		TGF-β Receptor Cancer
    SD-208 (GMP) is SD-208 (HY-13227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, and > 100-fold selectivity over TGF-βRII.
    SD-208

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: